Trial Profile

A Single-Arm, Open-Label Clinical Phase II Trial of the Safety and Immunogenicity of PDS0101 in People Living With HIV

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PDS 0101 (Primary)
Indications Anal intraepithelial neoplasia
Focus Adverse reactions

Most Recent Events

01 Oct 2025 Planned initiation date changed from 31 Jul 2025 to 20 Oct 2025.
29 Jul 2025 Status changed from planning to not yet recruiting.
01 Mar 2022 According to an PDS Biotechnology Corporation, updates from this study will be presented at the Oppenheimer's 32nd Annual Virtual Healthcare Conference, 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com